8431 results for "canc*"

in 25.85 milliseconds.

• EGAD00000000049

  RNA-SEQ data from oestrogen-receptor-alpha-positive metastatic lobular breast cancer sample

  Dataset EGAD00000000049

• EGAD00000000048

  Sequencing data from oestrogen-receptor-alpha-positive metastatic lobular breast cancer sample

  Dataset EGAD00000000048

• EGAD00000000013

  WTCCC1 project Breast cancer (BC) samples

  Dataset EGAD00000000013

• FFPE tumor RNA exome capture sequencing

  This dataset includes raw, untrimmed FASTQ files generated from bulk RNA exome capture sequencing of FFPE tumor samples from 268 stage III colorectal cancer patients, prior to receiving adjuvant chemotherapy treatment. RNA libraries were prepared with the Illumina TruSeq RNA Exome kit and sequenced (PE51bp) using an Illumina NovaSeq 6000 with an S4 flow cell. The metadata file "RNAseq_metadata.tsv" contains columns with relevant quality metrics "DV200" and "cDNA_ng_ul" per sample, and a column indicating whether the sample was part of one or more published analyses: Franken et al., Eur. J. Cancer, 2026. PMID: 41650786. DOI: https://doi.org/10.1016/j.ejca.2026.116262 Crnovrsanin et al., XXX, 2026. PMID: XXX. DOI: XXX

  Dataset EGAD50000002440

• Biomarker analysis and treatment dynamics following preoperative ipilimumab plus nivolumab in locally advanced urothelial cancer from the phase 1B NABUCCO study

  In the current analysis of the full NABUCCO trial population (cohorts 1 and 2), we aimed to explore both potential biomarkers for response to combination ICB, as well as treatment dynamics to gain a better understanding of the effects of ICB on the urothelial cancer tumor microenvironment (TME).

  Study EGAS50000001781

• Whole transcriptome sequencing of the dMMR colorectal cancer cohort

  We leveraged the ImmunoID NeXT platform, an Immune-enhanced multiomics platform to profile a cohort of patients with dMMR CRC. This sub-study includes the whole transriptome sequencing data

  Study EGAS50000001742

• TCR and BCR sequencing of the dMMR colorectal cancer cohort

  We leveraged the ImmunoID NeXT platform, an Immune-enhanced multiomics platform to profile a cohort of patients with dMMR CRC. This sub-study includes the TCR and BCR sequencing data

  Study EGAS50000001743

• ecDNA copy number heterogeneity

  Neuroblastoma exhibits significant inter- and intra-tumour genetic heterogeneity and varying clinical outcomes. Here, we used DNA and RNA sequencing from the same single cells in cell lines and neuroblastoma patients to investigate these effects. We reveal extensive intercellular ecDNA copy number heterogeneity. We also provide direct evidence of how this heterogeneity influences the expression of cargo genes, including MYCN and its downstream targets, and the overall transcriptional state of neuroblastoma cells.

  Study EGAS50000000509

• Parallel sequencing of extrachromosomal circular DNAs and transcriptomes in single cancer cells

  Study EGAS00001007026

• Multi-omics datasets (WES, RNA-seq) of mesothelioma MIST2 study, a phase II CDK4/6 (abemaciclib) clinical trial

  This study comprises 26 mesothelioma patients with whole exome and RNA sequencing, to to assess potential sensitivity to CDK4/6 inhibition in p16ink4A-negative mesothelioma.

  Study EGAS50000001823